phentermine | Evidence search

Controlled drugs and drug dependence | Medicines guidance

Source: British National Formulary - BNF - 11 June 2020

buprenorphine , gabapentin , mazindol, meprobamate, midazolam , pentazocine, phentermine, pregabalin, temazepam , and tramadol...

More: Prescribing and Technical Information

Controlled drugs and drug dependence | Medicines guidance

Source: British National Formulary for Children - BNFc - 11 June 2020

buprenorphine , gabapentin , mazindol, meprobamate, midazolam , pentazocine, phentermine, pregabalin, temazepam , and tramadol...

More: Prescribing and Technical Information

New product: Sunosi (solriamfetol) 75 and 150 mg film-coated tablets

Source: electronic Medicines Compendium - eMC - 22 January 2020 - Publisher: electronic Medicines compendium

Solriamfetol is licensed to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy (with/without cataplexy) or with obstructive sleep apnoea (OSA), whose...

Read Summary

- More: Prescribing and Technical Information

- More: Medicines Current Awareness

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

17 December 2019 - Publisher: The Lancet

RCT (n=119) found that fenfluramine 0.7 & 0.2mg/kg showed a 62.3% &32.4% greater reduction in monthly convulsive seizure frequency vs placebo (p<0.0001 & p=0.0209 for difference respectively).

SPS comment

- More: Primary Research

- More: Medicines Current Awareness

Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.

Source: PubMed - 26 November 2019 - Publisher: Expert review of clinical pharmacology

weight with orlistat (N=10,435; ∆ -3.07 Kg, 95% CI, -3.76 to -2.37), phentermine plus topiramate (N=2985; ∆ -9.77 Kg; 95% CI, -11.73 to...

Read Summary

- More: Systematic Reviews

Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis.

Source: PubMed - 31 July 2019 - Publisher: The Journal of clinical endocrinology and metabolism

enzyme inhibitors, angiotensin II receptor blockers, metformin, orlistat, phentermine-topiramate and pioglitazone significantly reduced...

Read Summary

- More: Systematic Reviews

Primary prevention of ASCVD and T2DM in patients at metabolic risk

Source: Endocrine Society - 31 July 2019 - Publisher: Endocrine Society

The 2019 guideline on metabolic risk: Updates the previous recommendations on this topic from the 2008 guideline – particularly those on elevated lipids and blood pressure – to reflect more...

Read Summary

- More: Guidance

Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: a randomized placebo-controlled pilot trial

Source: Cochrane Central Register of Controlled Trials - 01 July 2019 - Publisher: Metabolism: clinical and experimental

Background: This pilot study evaluated whether adding phentermine to liraglutide would induce further weight loss in participants who...

Read Summary

- More: Primary Research

Comprehensive type 2 diabetes management algorithm - 2019 executive summary [PDF]

01 February 2019 - Publisher: American Association of Clinical Endocrinologists

This algorithm for the comprehensive management of persons with type 2 diabetes (T2D) was developed to provide clinicians with a practical guide that considers the whole patient, his or her...

Read Summary

- More: Guidance

Care of women with obesity in pregnancy: green-top guideline no 72

22 November 2018 - Publisher: British Journal of Obstetrics and Gynaecology

Obesity is one of the most common health risk factors in pregnancy (latest figures show 22% of pregnant women in England are obese). This guidance includes recommendations on how to manage weight...

SPS comment

- More: Guidance

Qsiva | European Medicines Agency

Source: European Medicines Agency - EMA - 18 October 2018

"EMA_News" } RSS phentermine / topiramate Table of contents Overview

More: Prescribing and Technical Information

The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea : An Official American Thoracic Society Clinical Practice Guideline [PDF]

15 September 2018 - Publisher: American Thoracic Society

The purpose of this guideline is to provide evidence-based recommendations for the management of overweight/obesity in patients with obstructive sleep apnea (OSA).

Read Summary

- More: Guidance

ACR-ACNM Practice Parameter for the Performance of Dopamine (DaT) Transporter Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders [PDF]

Source: American College of Radiology - 18 December 2017

d-amphetamine, methamphetamine, methylphenidate : CNS stimulants: ephedrine, phentermine Drugs that do not increase or decrease striatal...

More: Guidance

Obesity

Source: Clinical Knowledge Summaries - CKS - 01 December 2017

naltrexone-bupropion, and phentermine-topiramate) were all associated with achieving at least 5% weight loss at 52 weeks. Liraglutide...

More: Guidance

Drug misuse and dependence: UK guidelines on clinical management [PDF]

Source: Department of Health - 17 July 2017 - Publisher: Department of Health

The 2017 update offers guidance on; prison-based treatment; new psychoactive substances and club drugs; mental health co-morbidity; misuse of prescribed and over-the-counter medicines; stopping...

SPS comment

- More: Guidance

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

14 March 2017 - Publisher: Diabetes Care

This RCT (n=355) reports an absolute reduction in weight of 0.6kg with placebo, 1.9kg with canagliflozin (C), 4.1kg with phentermine (P) and 7.3kg with combination C+P over 26-weeks. C+P also had...

SPS comment

- More: Primary Research

Pediatric obesity - assessment, treatment, and prevention: an Endocrine Society clinical practice guideline [PDF]

Source: Endocrine Society - 01 March 2017 - Publisher: Endocrine Society

EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the...

Read Summary

- More: Guidance

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

23 February 2017 - Publisher: The Lancet

By week 160, 26 (2%) of 1472 on liraglutide (LG) vs. 46 (6%) of 738 on placebo were diagnosed with diabetes (DB) while on treatment. Time to onset of DB was 2.7 times longer with LG vs. placebo (HR...

SPS comment

- More: Primary Research

General practice management of type 2 diabetes 2016–18 [PDF]

01 September 2016 - Publisher: Royal Australian College of General Practitioners;Diabetes Australia

These Australian guidelines have been designed to provide pragmatic, evidence-based recommendations for use in general practice and adopt the most recent recommendations from organisations...

Read Summary

- More: Guidance

Safety in lactation: Drugs for obesity

Source: Specialist Pharmacy Service - 08 August 2016

Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Orlistat is the only drug licensed…

More: Prescribing and Technical Information

The safer management of controlled drugs: Annual report 2015 [PDF]

Source: Care Quality Commission - CQC - 15 July 2016 - Publisher: Care Quality Commission

In this report, the CQC makes 3 recommendations to strengthen existing arrangements for reporting and sharing of controlled drug concerns across England. It showcases local and national initiatives...

Read Summary

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis

15 June 2016 - Publisher: Journal of the American Medical Association

Review of 28 RCTs found in overweight/obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate (PT), and liraglutide were associated with achieving at least 5% weight loss at...

SPS comment

- More: Systematic Reviews

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis

Source: PubMed - 14 June 2016 - Publisher: Jama

long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year...

Read Summary

- More: Systematic Reviews

Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis

06 June 2016 - Publisher: International Journal of Clinical Practice

In this review of 9 studies (6 RCTs) a meta-analysis of 3 of the RCTs (n=121) found that orlistat and metformin had similar positive effects on BMI, testosterone and insulin in overweight/obese PCOS...

Read Summary

- More: Systematic Reviews

How should dentists prescribe, store, order and dispose of controlled drugs?

Source: Specialist Pharmacy Service - 06 June 2016

This updated Q&A aims to explain controlled drug legislation relevant to primary care dental practice. Includes prescribing for NHS and private patients, ordering/requisitioning, storage and…

More: Evidence Summaries

AACE/ACE clinical practice guidelines for comprehensive medical care of patients with obesity

10 May 2016 - Publisher: American Association of Clinical Endocrinologists

Development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and the American College of Endocrinology (ACE) Board of Trustees and...

Read Summary

- More: Guidance

Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers

07 April 2016 - Publisher: British Journal of Clinical Pharmacology

Raynaud’s phenomenon (RP) is likely an underestimated adverse drug event, with limited available evidence regarding its prevalence. This review identified 12 classes of drugs responsible for RP.

Read Summary

- More: Systematic Reviews

Long‐term effects of weight‐reducing drugs in people with hypertension

Source: Cochrane Database of Systematic Reviews - 02 March 2016

additional study of phentermine/topiramate, bringing the total number of studies to nine that compare orlistat, sibutramine, or...

More: Systematic Reviews

A Comparison of New Pharmacological Agents for the Treatment of Obesity

Source: PubMed - 17 February 2016 - Publisher: The Annals Of Pharmacotherapy

between these agents at this point, which limits comparisons across agents. Phentermine/topiramate ER appeared to have the best overall...

Read Summary

- More: Systematic Reviews

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003–2012

28 January 2016 - Publisher: PLOS Medicine

UK self-regulatory approach (AP), which relies mainly on complaints from company outsiders, can detect and deal with instances of off-label promotion with high visibility (e.g. adverts), but it may...

Read Summary

- More: Primary Research

ASGE position statement on endoscopic bariatric therapies in clinical practice [PDF]

Source: American Society for Gastrointestinal Endoscopy - 01 November 2015 - Publisher: American Society for Gastrointestinal Endoscopy

The American Society for Gastrointestinal Endoscopy (ASGE), as well as a number of federal agencies and medical societies, recognizes obesity as a disease requiring primary therapy.1 In 2011, the...

Read Summary

- More: Guidance

LMEN: Naltrexone and bupropion for weight management in adults (June 2015)

Source: Specialist Pharmacy Service - 25 June 2015

Naltrexone and bupropion prolonged-release tablets (Mysimba by Orexigen Therapeutics Ireland Limited), is a new treatment option for weight management as an adjunct to a reduced…

More: Prescribing and Technical Information

Smoking, nutrition, alcohol, physical activity (SNAP): a population health guide to behavioural risk factors in general practice 2nd edition [PDF]

18 March 2015 - Publisher: Royal Australian College of General Practitioners

This Australian guide has been designed to assist general practitioners (GPs) and practice staff to work with patients on the lifestyle risk factors of smoking, nutrition, alcohol and physical...

Read Summary

- More: Guidance

Pharmacological management of obesity : an Endocrine Society clinical practice guideline

Source: Endocrine Society - 01 January 2015 - Publisher: Endocrine Society

Apovian, CM et al. (2015) Pharmacological management of obesity:an Endocrine Society clinical practice guideline, The journal of clinical endocrinology and metabolism, Vol.100(2) pp. 342-62 This...

Read Summary

- More: Guidance

Cost-effectiveness analysis of qsymia for weight loss

Source: NHS Economic Evaluation Database - NHS EED - 31 July 2014

Anti-Obesity Agents; Appetite Depressants; Costs and Cost Analysis; Humans; Phentermine AccessionNumber 22014027855 Date bibliographic...

Read Summary

- More: Economic Evaluations

Drug use, impaired driving and traffic accidents [PDF]

Source: European Monitoring Centre for Drugs and Drug Addiction - 01 June 2014

namely amphetamine, methamphetamine, MDMA, ephedrine, pseudoephedrine, phentermine and cocaine. There was no significant association...

More: Evidence Summaries

Pheochromocytoma and paraganglioma : an Endocrine Society clinical practice guideline

Source: Endocrine Society - 01 June 2014 - Publisher: Endocrine Society

Lenders JWM (2014) Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline, Journal of Clinical Endocrinology & Metabolism, Vol.99(6) pp.1915–1942 OBJECTIVE: ...

Read Summary

- More: Guidance

Addiction potential of phentermine prescribed during long-term treatment of obesity

Source: Medicines Management Collection - 08 May 2014 - Publisher: International Journal of Obesity

Objective: To investigate if phentermine treatment induces phentermine abuse, psychological dependence (addiction) or...

Read Summary

- More: Primary Research

Drug use, impaired driving and traffic accidents (2nd edition) [PDF]

Source: European Monitoring Centre for Drugs and Drug Addiction - 01 May 2014 - Publisher: European Monitoring Centre for Drugs and Drug Addiction

Insights series This literature review provides a comprehensive report on the relationship between drug use, impaired driving and traffic accidents. It describes methodological issues, presents...

Read Summary

- More: Primary Research

National report 2013: France [PDF]

Source: European Monitoring Centre for Drugs and Drug Addiction - 01 May 2014

galenical forms of phentermine and cathinones on the narcotics list:  Order of 14 February 201257 on the classification of all...

More: Evidence Summaries

American Society of Interventional Pain Physicians (ASIPP) : guidelines for responsible opioid prescribing in chronic non-cancer pain : part 2 - guidance [PDF]

01 January 2014 - Publisher: American Society of Interventional Pain Physicians

Background: Opioid abuse has continued to increase at an alarming rate since the 1990s. As documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement...

Read Summary

- More: Guidance

Use of prescription antiobesity drugs in the United States

Source: Medicines Management Collection - 05 December 2013 - Publisher: Pharmacotherapy

approximately 2.74 million patients used antiobesity drugs, predominantly phentermine (2.43 million patients). The use of...

Read Summary

- More: Primary Research

Psychoactive substance use by truck drivers : a systematic review

21 October 2013 - Publisher: BMJ Group

Girotto,E., Mesas,A.E., de Andrade,S.M. et al (2013) Psychoactive substance use by truck drivers: a systematic review. Occupational and Environmental Medicine. E-pub ahead of print. This...

Read Summary

- More: Systematic Reviews

National report 2012: France [PDF]

Source: European Monitoring Centre for Drugs and Drug Addiction - 01 June 2013

of dangerous substances and to classify all pharmaceutical forms of "phentermine" as narcotics: : Decree of 25 July 201152, which...

More: Evidence Summaries

National report 2012: Italy [PDF]

Source: European Monitoring Centre for Drugs and Drug Addiction - 01 June 2013

additions, moving the drugs Amfepramone (diethylpropion), Phendimetrazine, Phentermine and Mazindol into Table I." Ministerial Decree of...

More: Evidence Summaries

Qsymia (phentermine/topiramate; Vivus Inc.) for obesity management

Source: Centre for Reviews and Dissemination Health Technology Assessments - CRD HTA - 23 April 2013 - Publisher: Centre for Reviews and Dissemination

Qsymia (phentermine/topiramate; Vivus Inc.) for obesity management Record Status

Read Summary

- More: Health Technology Assessments

Mortality among people who inject drugs : a systematic review and meta-analysis

Source: World Health Organization - 01 February 2013 - Publisher: World Health Organization (WHO)

Mathers BM, Degenhardt L, Bucello C, et al. (2013) Mortality among people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health Organization 91: 102-213 This...

Read Summary

- More: Systematic Reviews

Mortality among people who inject drugs : a systematic review and meta-analysis

Source: World Health Organization - 01 February 2013 - Publisher: World Health Organization (WHO)

Mathers BM, Degenhardt L, Bucello C et al. (2013) Mortality among people who inject drugs: A systematic review and meta-analysis. Bulletin of the World Health Organization 91: 102-23 This...

Read Summary

- More: Systematic Reviews

National report 2011: Hungary [PDF]

Source: European Monitoring Centre for Drugs and Drug Addiction - 01 November 2012

2010 were the following: p-fluoroamphetamine, trimethoxyamphetamine, phentermine. In 2010 a total of 18,411 tablets containing illicit...

More: Evidence Summaries

Cardiovascular risk assessment in the development of new drugs for obesity

Source: Medicines Management Collection - 19 September 2012 - Publisher: Journal of the American Medical Association

from 3% for lorcaserin (approved in Jun 2012) to 9% for phentermine/topiramate. Cardiovascular safety information about...

Read Summary

- More: Primary Research

Filter results by

Results for phentermine 1 - 50 of 65 sorted by relevance / date

Comprehensive type 2 diabetes management algorithm - 2019 executive summary [PDF]

The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea : An Official American Thoracic Society Clinical Practice Guideline [PDF]

ACR-ACNM Practice Parameter for the Performance of Dopamine (DaT) Transporter Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders [PDF]

Drug misuse and dependence: UK guidelines on clinical management [PDF]

Pediatric obesity - assessment, treatment, and prevention: an Endocrine Society clinical practice guideline [PDF]

General practice management of type 2 diabetes 2016–18 [PDF]

The safer management of controlled drugs: Annual report 2015 [PDF]

ASGE position statement on endoscopic bariatric therapies in clinical practice [PDF]

Smoking, nutrition, alcohol, physical activity (SNAP): a population health guide to behavioural risk factors in general practice 2nd edition [PDF]

Drug use, impaired driving and traffic accidents [PDF]

Drug use, impaired driving and traffic accidents (2nd edition) [PDF]

National report 2013: France [PDF]

American Society of Interventional Pain Physicians (ASIPP) : guidelines for responsible opioid prescribing in chronic non-cancer pain : part 2 - guidance [PDF]

National report 2012: France [PDF]

National report 2012: Italy [PDF]

National report 2011: Hungary [PDF]